Biomarin Pharmaceutical advertising spend, FY2025
Biomarin Pharmaceutical (BMRN) reported $50.5M of advertising expense for the fiscal year ended Dec 31, 2025. That is 1.6% of revenue of $3.2B. Up 46.4% from FY2024.
Key facts
- Ad spend is 1.7x its FY2020 level ($29.3M), in line with revenue (1.7x).
- FY2025 is the highest year on file, going back to FY2020.
- Largest increase +46.4% in FY2025; largest cut -16.6% in FY2022.
- Ad spend has risen 3 years in a row.
- Ad spend is 1.6% of revenue, about the same as 1.6% in FY2020.
- Biomarin Pharmaceutical spends more on advertising than 1% of the 458 US-listed companies tracked. Its ad-to-revenue ratio is below the median of 4.5%.
Ad spend by fiscal year
Ad spend as % of revenue
Ad spend in context, FY2025
Advertising was 4.4% of selling, general and administrative expense. Research and development spending was 18x advertising. Advertising equalled 12.3% of operating income.
| Advertising | $50.5M | AdvertisingExpense |
|---|---|---|
| Selling, general and administrative | $1.2B | ad spend = 4.4% |
| Research and development | $922M | R&D = 18x ad spend |
| Operating income | $409M | ad spend = 12.3% |
| Net income | $349M |
Same fiscal year and filing as the ad spend. Selling and marketing and SG&A usually include advertising.
History
Download CSV| Fiscal year | Period end | Ad spend | YoY | Revenue | Ad / revenue | Tag | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | $50.5M | +46.4% | $3.2B | 1.6% | AdvertisingExpense | 10-K Feb 26, 2026 |
| FY2024 | Dec 31, 2024 | $34.5M | +24.1% | $2.9B | 1.2% | AdvertisingExpense | 10-K Feb 26, 2026 |
| FY2023 | Dec 31, 2023 | $27.8M | +10.3% | $2.4B | 1.1% | AdvertisingExpense | 10-K Feb 26, 2026 |
| FY2022 | Dec 31, 2022 | $25.2M | -16.6% | $2.1B | 1.2% | AdvertisingExpense | 10-K Feb 24, 2025 |
| FY2021 | Dec 31, 2021 | $30.2M | +3.1% | $1.8B | 1.6% | AdvertisingExpense | 10-K Feb 26, 2024 |
| FY2020 | Dec 31, 2020 | $29.3M | n/a | $1.9B | 1.6% | AdvertisingExpense | 10-K Feb 27, 2023 |
Ad spend, revenue and the ratio come from the linked filing. YoY compares each year with the fiscal year directly before it, under the same tag. A gap, a change of tag or a change of fiscal year end leaves it blank.
What the figure is
Advertising costs as disclosed in the annual report (XBRL tag AdvertisingExpense).
Compared with similar spenders
The 6 companies closest to Biomarin Pharmaceutical in latest-year ad spend.
| Rank | Company | Ad spend | Ad / revenue | YoY | Fiscal year |
|---|---|---|---|---|---|
| 450 | Exelixis | $51.7M | 2.2% | +18.9% | FY2025 |
| 451 | Lindblad Expeditions | $51.7M | 6.7% | +31.2% | FY2025 |
| 452 | ThredUp | $51.1M | 16.4% | +23.1% | FY2025 |
| 453 | OppFi | $50.9M | 13.4% | +3.4% | FY2025 |
| 454 | Biomarin Pharmaceutical | $50.5M | 1.6% | +46.4% | FY2025 |
| 455 | Dolby Laboratories | $50.3M | 3.5% | -1.3% | FY2026 |
| 456 | Agilent Technologies | $50M | 0.7% | +2.0% | FY2025 |
Full ranking of 458 companies · Biggest increases #38 · New $50M spenders #22
Questions
How much does Biomarin Pharmaceutical spend on advertising?
Biomarin Pharmaceutical spent $50.5M on advertising in fiscal 2025, the year ended Dec 31, 2025, according to its 10-K filed Feb 26, 2026.
What percentage of revenue does Biomarin Pharmaceutical spend on advertising?
1.6% of revenue in fiscal 2025 ($50.5M against $3.2B). The median across the 458 companies tracked is 4.5%.
Is Biomarin Pharmaceutical spending more on advertising?
Yes. Ad spend rose 46.4% in fiscal 2025 from fiscal 2024. It has risen 3 years in a row.
How does Biomarin Pharmaceutical rank by advertising spend?
#454 of 458 US-listed companies with $50M or more in ad spend, ranked on each company's latest fiscal year.
Does Biomarin Pharmaceutical spend more on advertising than on R&D?
No. In fiscal 2025 it spent $922M on research and development and $50.5M on advertising.
What does Biomarin Pharmaceutical's advertising figure include?
Advertising costs as disclosed in the annual report (XBRL tag AdvertisingExpense).
Company and source
- Filing
- 10-K for FY2025, filed Feb 26, 2026
- Accession number
0001048477-26-000004- Company
- BIOMARIN PHARMACEUTICAL INC, CIK 1048477, SIC 2834 (Pharmaceutical Preparations)
- Headquarters
- Novato, CA
- Incorporated in
- DE
- Fiscal year ends
- December 31
- Listed on
- Nasdaq
- SEC filer status
- Large accelerated filer
- Data
- SEC EDGAR XBRL company facts, retrieved Nov 18, 2026. Methodology.
- Cite
- Biomarin Pharmaceutical advertising spend, FY2020-FY2025. Aleksei Trudov, io.trudov.com, from SEC EDGAR XBRL company facts (latest: 10-K filed Feb 26, 2026), retrieved Nov 18, 2026. https://io.trudov.com/company/biomarin-pharmaceutical/advertising-spend/
- Download
- CSV, all years · CSV, all 458 companies